Protective Role of Ramipril and Candesartan against Myocardial Ischemic Reperfusion Injury: A Biochemical and Transmission Electron Microscopical Study

Q1 Pharmacology, Toxicology and Pharmaceutics

Advances in Pharmacological Sciences Pub Date : 2016-03-06 DOI:10.1155/2016/4608979

M. S. T. Sheik Uduman, Rajitha Reddy, Priyanka Punuru, G. Chakka, G. Karunakaran

{"title":"Protective Role of Ramipril and Candesartan against Myocardial Ischemic Reperfusion Injury: A Biochemical and Transmission Electron Microscopical Study","authors":"M. S. T. Sheik Uduman, Rajitha Reddy, Priyanka Punuru, G. Chakka, G. Karunakaran","doi":"10.1155/2016/4608979","DOIUrl":null,"url":null,"abstract":"The present study was designed to investigate the role of combined administration of Ramipril and Candesartan against in vitro myocardial ischemic reperfusion injury in rat. Male Wistar albino rats were divided into five groups (n = 6) and treated with saline (10 mL/kg), Ramipril (2 mg/kg), Candesartan (1 mg/kg), and the combination of both drugs, respectively 24 h before induction of global ischemia (5 min of stabilization, 9 min of global ischemia, and 12 min of reflow). Combination of Ramipril and Candesartan when compared to the monotherapy significantly increased the levels of superoxide dismutase, reduced glutathione, catalase, and nitric oxide and decreased the levels of thiobarbituric acid reactive substances. In addition, the superior protective role of combination of Ramipril and Candesartan on ischemia induced myocardial damage was further confirmed by well preserved myocardial tissue architecture in light microscopy and transmission electron microscopy analysis studies. The combination was proved to be effective in salvaging the myocardial tissue against ischemic reperfusion injury when compared to the monotherapy of individual drugs and further investigations on protective mechanism of drugs by increasing the nitric oxide level at molecular levels are needed.","PeriodicalId":7389,"journal":{"name":"Advances in Pharmacological Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/4608979","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Pharmacological Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2016/4608979","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 7

Abstract

The present study was designed to investigate the role of combined administration of Ramipril and Candesartan against in vitro myocardial ischemic reperfusion injury in rat. Male Wistar albino rats were divided into five groups (n = 6) and treated with saline (10 mL/kg), Ramipril (2 mg/kg), Candesartan (1 mg/kg), and the combination of both drugs, respectively 24 h before induction of global ischemia (5 min of stabilization, 9 min of global ischemia, and 12 min of reflow). Combination of Ramipril and Candesartan when compared to the monotherapy significantly increased the levels of superoxide dismutase, reduced glutathione, catalase, and nitric oxide and decreased the levels of thiobarbituric acid reactive substances. In addition, the superior protective role of combination of Ramipril and Candesartan on ischemia induced myocardial damage was further confirmed by well preserved myocardial tissue architecture in light microscopy and transmission electron microscopy analysis studies. The combination was proved to be effective in salvaging the myocardial tissue against ischemic reperfusion injury when compared to the monotherapy of individual drugs and further investigations on protective mechanism of drugs by increasing the nitric oxide level at molecular levels are needed.

查看原文本刊更多论文

雷米普利和坎地沙坦对心肌缺血再灌注损伤的保护作用:生化和透射电镜研究

本研究旨在探讨雷米普利和坎地沙坦联合给药对大鼠体外心肌缺血再灌注损伤的作用。雄性Wistar白化大鼠分为5组(n = 6)，分别于诱导全脑缺血前24 h(稳定5min、全脑缺血9min、回流12min)给予生理盐水(10ml /kg)、雷米普利(2mg /kg)、坎地沙坦(1mg /kg)及两药联合治疗。与单药治疗相比，雷米普利和坎地沙坦联合治疗显著增加了超氧化物歧化酶、还原性谷胱甘肽、过氧化氢酶和一氧化氮的水平，并降低了硫巴比妥酸反应性物质的水平。此外，在光镜和透射电镜分析研究中，保存完好的心肌组织结构进一步证实了雷米普利和坎地沙坦联用对缺血心肌损伤的优越保护作用。与单药治疗相比，联合用药对心肌组织缺血再灌注损伤有较好的挽救作用，需要进一步从分子水平上研究药物通过提高一氧化氮水平的保护机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Pharmacological Sciences PHARMACOLOGY & PHARMACY-

CiteScore

6.40

自引率

0.00%

发文量

审稿时长

14 weeks

期刊介绍： Advances in Pharmacological and Pharmaceutical Sciences is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies in all areas of experimental and clinical pharmacology, pharmaceutics, medicinal chemistry and drug delivery. Topics covered by the journal include, but are not limited to: -Biochemical pharmacology, drug mechanism of action, pharmacodynamics, pharmacogenetics, pharmacokinetics, and toxicology. -The design and preparation of new drugs, and their safety and efficacy in humans, including descriptions of drug dosage forms. -All areas of medicinal chemistry, such as drug discovery, design and synthesis. -Basic biology of drug and gene delivery through to application and development of these principles, through therapeutic delivery and targeting. Areas covered include bioavailability, controlled release, microcapsules, novel drug delivery systems, personalized drug delivery, and techniques for passing biological barriers.